Romanyuk Nataliya, Amemori Takashi, Turnovcova Karolina, Prochazka Pavel, Onteniente Brigitte, Sykova Eva, Jendelova Pavla
Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Cell Transplant. 2015;24(9):1781-97. doi: 10.3727/096368914X684042. Epub 2014 Aug 19.
Despite advances in our understanding and research of induced pluripotent stem cells (iPSCs), their use in clinical practice is still limited due to lack of preclinical experiments. Neural precursors (NPs) derived from a clone of human iPSCs (IMR90) were used to treat a rat spinal cord lesion 1 week after induction. Functional recovery was evaluated using the BBB, beam walking, rotarod, and plantar tests. Lesion morphology, endogenous axonal sprouting, graft survival, and iPSC-NP differentiation were analyzed immunohistochemically. Quantitative polymerase chain reaction (qPCR) was used to evaluate the effect of transplanted iPSC-NPs on endogenous regenerative processes and also to monitor their behavior after transplantation. Human iPSC-NPs robustly survived in the lesion, migrated, and partially filled the lesion cavity during the entire period of observation. Transplanted animals displayed significant motor improvement already from the second week after the transplantation of iPSC-NPs. qPCR revealed the increased expression of human neurotrophins 8 weeks after transplantation. Simultaneously, the white and gray matter were spared in the host tissue. The grafted cells were immunohistochemically positive for doublecortin, MAP2, βIII-tubulin, GFAP, and CNPase 8 weeks after transplantation. Human iPSC-NPs further matured, and 17 weeks after transplantation differentiated toward interneurons, dopaminergic neurons, serotoninergic neurons, and ChAT-positive motoneurons. Human iPSC-NPs possess neurotrophic properties that are associated with significant early functional improvement and the sparing of spinal cord tissue. Their ability to differentiate into tissue-specific neurons leads to the long-term restoration of the lesioned tissue, making the cells a promising candidate for future cell-based therapy of SCI.
尽管我们在诱导多能干细胞(iPSC)的理解和研究方面取得了进展,但由于缺乏临床前实验,它们在临床实践中的应用仍然有限。源自人类iPSC(IMR90)克隆的神经前体细胞(NP)在诱导后1周用于治疗大鼠脊髓损伤。使用BBB、梁式行走、转棒和足底试验评估功能恢复情况。通过免疫组织化学分析损伤形态、内源性轴突发芽、移植物存活和iPSC-NP分化情况。定量聚合酶链反应(qPCR)用于评估移植的iPSC-NP对内源性再生过程的影响,并监测其移植后的行为。在整个观察期内,人类iPSC-NP在损伤部位强劲存活、迁移并部分填充损伤腔。移植iPSC-NP后的第二周,移植动物的运动功能就有了显著改善。qPCR显示移植8周后人类神经营养因子的表达增加。同时,宿主组织中的白质和灰质得以保留。移植8周后,移植细胞对双皮质素、微管相关蛋白2(MAP2)、βIII微管蛋白、胶质纤维酸性蛋白(GFAP)和2',3'-环核苷酸3'-磷酸二酯酶(CNPase)免疫组织化学呈阳性。人类iPSC-NP进一步成熟,移植17周后分化为中间神经元、多巴胺能神经元、5-羟色胺能神经元和胆碱乙酰转移酶(ChAT)阳性运动神经元。人类iPSC-NP具有神经营养特性,与早期显著的功能改善和脊髓组织的保留有关。它们分化为组织特异性神经元的能力导致损伤组织的长期修复,使这些细胞成为未来脊髓损伤细胞治疗的有希望的候选者。